Advancing Precision Radiation Oncology in Head and Neck Cancers

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: 31 July 2026 | Viewed by 872

Special Issue Editor


E-Mail Website
Guest Editor
Department of Radiation Oncology, Proton and Radiation Therapy Center, Chang Gung Memorial Hospital—Linkou Medical Center, 5 Fu-Shin Street, Kwei-Shan, Taoyuan 333, Taiwan
Interests: radiotherapy; oncology; immunotherapy; radiomics; oncogenetics; proton therapy

Special Issue Information

Dear Colleagues,

This Special Issue, "Advancing Precision Radiation Oncology in Head and Neck Cancers," will highlight the latest translational and clinical advances driving personalized radiotherapy for head and neck malignancies. Head and neck cancers, particularly squamous cell carcinoma, exhibit significant biological and molecular heterogeneity, which impacts treatment response and outcomes. Recent research has elucidated the roles of the tumor microenvironment, DNA damage response pathways, and immune modulation in radioresistance, offering new targets for radiosensitization and combination therapies.

Precision radiation oncology leverages genomic, transcriptomic, and imaging biomarkers to tailor treatment plans, moving beyond the traditional one-size-fits-all approach. Innovations such as the radiosensitivity index and radiomics enable non-invasive, longitudinal assessment of tumor biology and heterogeneity, facilitating adaptive and individualized therapy. Genomically guided radiation therapy is increasingly recognized as essential for improving outcomes and minimizing toxicity, as emphasized by the American Society for Radiation Oncology, the American Association of Physicists in Medicine, and the National Cancer Institute.

This Special Issue will feature original research, reviews, and expert perspectives on molecular profiling, biomarker-driven treatment adaptation, novel radiosensitizers, and informatics infrastructure for precision medicine in radiation oncology. The goal is to accelerate the integration of precision strategies into routine clinical practice, ultimately improving survival and quality of life for patients with head and neck cancers.

Dr. Wing-Keen Yap
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • precision radiation oncology
  • head and neck cancers
  • oncogenetics
  • genomic biomarkers
  • radiosensitivity
  • adaptive radiotherapy
  • artificial intelligence
  • immunotherapy integration
  • proton therapy
  • deescalation strategies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 1526 KB  
Article
Longitudinal Monitoring of Pan-Immune–Inflammation Value Forecast Outcomes for Patients with Head and Neck Cancer Treated with Chemoradiotherapy or Radiotherapy: Results from a Large Cohort Study
by Sean Hsiang-Ting Chen, Tsung-You Tsai, Rodney Cheng-En Hsieh, Kai-Ping Chang, Chung-Jan Kang, Yi-An Lu, Pei-Wei Huang, Miao-Fen Chen, Chien-Yu Lin, Shanli Ding, Ngan-Ming Tsang, Wen-Hsin Lu, Wing-Keen Yap and Alex Chia-Hsin Lin
Biomedicines 2026, 14(4), 830; https://doi.org/10.3390/biomedicines14040830 - 5 Apr 2026
Viewed by 611
Abstract
Background/Objectives: We aim to investigate whether tracking pan-immune–inflammation value (PIV) dynamics during radiotherapy (RT) can inform real-time prognosis in patients with head and neck cancer (HNC). Methods: We retrospectively reviewed the medical records of patients with HNC who received RT at [...] Read more.
Background/Objectives: We aim to investigate whether tracking pan-immune–inflammation value (PIV) dynamics during radiotherapy (RT) can inform real-time prognosis in patients with head and neck cancer (HNC). Methods: We retrospectively reviewed the medical records of patients with HNC who received RT at our institution between 2005 and 2013. Temporal changes in the PIV throughout the RT were evaluated using the Friedman test and Wilcoxon signed-rank test. The PIV dynamics were quantified using PIV ratios, defined as the PIV at three distinct time points (PIV-2, PIV-4, and PIV-6) during treatment divided by the pretreatment PIV (PIV-0). Overall survival (OS) and progression-free survival (PFS) served as the primary and secondary endpoints analyzed. Results: A total of 676 patients with HNC were enrolled, with a median follow-up of 8.1 years. The PIV demonstrated a continuously ascending trend over time, with the most dramatic increase occurring six weeks after the start of RT. Compared with patients with a low PIV ratio at six weeks (PIV-6/PIV-0), those with a high PIV ratio showed more favorable survival outcomes (five-year OS: 58.9% versus 70.8%, p = 0.002; five-year PFS: 62.0% versus 71.1%, p = 0.013). The subgroup analyses yielded consistent results. Notably, the real-time risks of death and recurrence changed in parallel with the PIV dynamics. Multivariate analysis confirmed PIV-6/PIV-0 as an independent prognostic factor for both OS and PFS. Conclusions: Monitoring longitudinal PIV dynamics may assist in forecasting the OS and PFS in patients with HNC being treated with RT, thus enabling individualized, risk-adapted treatment management. Full article
(This article belongs to the Special Issue Advancing Precision Radiation Oncology in Head and Neck Cancers)
Show Figures

Figure 1

Back to TopTop